ADC Therapeutics (ADCT) Cash from Operations: 2018-2024
Historic Cash from Operations for ADC Therapeutics (ADCT) over the last 7 years, with Dec 2024 value amounting to -$123.8 million.
- ADC Therapeutics' Cash from Operations rose 77.12% to -$31.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$118.7 million, marking a year-over-year increase of 14.19%. This contributed to the annual value of -$123.8 million for FY2024, which is 4.34% down from last year.
- According to the latest figures from FY2024, ADC Therapeutics' Cash from Operations is -$123.8 million, which was down 4.34% from -$118.7 million recorded in FY2023.
- In the past 5 years, ADC Therapeutics' Cash from Operations ranged from a high of -$118.7 million in FY2023 and a low of -$233.4 million during FY2021.
- Moreover, its 3-year median value for Cash from Operations was -$123.8 million (2024), whereas its average is -$126.9 million.
- In the last 5 years, ADC Therapeutics' Cash from Operations crashed by 38.32% in 2021 and then soared by 40.74% in 2022.
- ADC Therapeutics' Cash from Operations (Yearly) stood at -$168.7 million in 2020, then tumbled by 38.32% to -$233.4 million in 2021, then skyrocketed by 40.74% to -$138.3 million in 2022, then rose by 14.19% to -$118.7 million in 2023, then fell by 4.34% to -$123.8 million in 2024.